Milestone Receives Nasdaq Bid-Price Deficiency Notice, 180 Days to April 21, 2027
MIST sits 20% above its 52-week low of $0.631.
Summary
Milestone received a Nasdaq notice on October 23, 2026 that its shares traded under $1.00 for 30 consecutive business days, giving it until April 21, 2027 to regain compliance or pursue a transfer to the Nasdaq Capital Market.
Key Events · Legal and Risk Events · MIST
-
Nasdaq Bid-Price Deficiency Notice
On October 23, 2026, Nasdaq notified Milestone that its common shares had closed below $1.00 for the previous 30 consecutive business days, breaching Listing Rule 5450(a)(1) for the Nasdaq Global Select Market.
-
180-Day Cure Window to April 21, 2027
The company has until April 21, 2027 to close at $1.00 or more for a minimum of 10 consecutive business days; the notice has no present impact on the listing.
-
Fallback: Capital Market Transfer
If it fails to cure, Milestone may apply to transfer to the Nasdaq Capital Market, paying a $5,000 application fee and meeting that market's other continued listing standards, and would need to state its intent to cure by reverse stock split if necessary.
-
Reverse Split Now on the Table
The company said it will monitor its bid price and consider available options, including transferring to the Nasdaq Capital Market or effecting a reverse stock split; it gave no assurance it will succeed.
Analysis · MIST · Life Sciences
Nasdaq has started the clock on a listing deficiency after Milestone's shares closed below $1.00 for 30 straight business days. To regain compliance, the bid must close at $1.00 or more for at least 10 consecutive business days by April 21, 2027; failing that, the company must apply to move to the Nasdaq Capital Market and signal it would use a reverse split if needed. Nothing changes today — the shares still trade on the Global Select Market — but a reverse split or a Capital Market transfer is now a live possibility, and both would reshape how the stock trades. The company also carries a $300M shelf and a $100M at-the-market program established in May 2026, so any equity raised while the stock sits under $1.00 would be sold at depressed levels.
How filings like this one have moved
In the 30 days to Oct 29, 2026, 39% of the 991 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MIST was trading at $0.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $94.3M. The 52-week trading range was $0.63 to $3.06. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.